BioAge Labs, Inc.
Financials
Valuation Metrics
BioAge Labs, Inc.'s Market Cap is $370M. At end of 2025 it was $474M. Ranked #2891 of 3,121 in US market (top 93%), #1291 of 1,463 on NASDAQ (top 88%), #234 of 266 in Pharmaceuticals, Biotechnology & Life Sciences (top 88%) by Market Cap.
Investment Metrics(as of 2026-09-18)
| Metric | Value | Rank |
|---|---|---|
| Size | ||
| Market Cap | $370M | US#2,891/3,121 Sec#234/266 |
| Revenue | $10M | US#2,835/3,121 Sec#171/266 |
| Net Income | $-94M | US—/3,121 Sec—/266 |
| Total Assets | $397M | US#2,845/3,121 Sec#188/266 |
| Net Assets | $375M | US#2,415/3,121 Sec#141/266 |
| Employees | 61 | US#2,694/3,121 Sec#202/266 |
| Value | ||
| P/B | 0.99x | US#372/3,121 Sec#12/266 |
| P/S | 35.72x | US#2,897/3,121 Sec#158/266 |
| FCF Yield | -23.81% | US—/3,121 Sec—/266 |
| Profitability | ||
| ROE | -25.20% | US#2,532/3,121 Sec#104/266 |
| ROA | -23.80% | US#2,841/3,121 Sec#139/266 |
| Op. Margin | -1026.28% | US#2,832/3,121 Sec#169/266 |
| Revenue Growth | 168.06% | US#60/3,121 Sec#23/266 |
| Financial Health | ||
| Debt Ratio | 5.87% | US#48/3,121 Sec#20/266 |
| Total Debt | $3M | US#2,949/3,121 Sec#230/266 |
| FCF | $-88M | US#2,615/3,121 Sec#135/266 |
| Cash | $74M | US#2,394/3,121 Sec#198/266 |
| Current Ratio | 17.19x | US#143/3,121 Sec#36/266 |
| Performance | ||
| 1Y Return | 54.41% | US#433/3,121 Sec#92/266 |
| 1M Return | -25.02% | US#3,011/3,121 Sec#248/266 |
| From 52W High | -68.95% | US#3,011/3,121 Sec#243/266 |
| 1Y MDD | -69.12% | US#2,945/3,121 Sec#236/266 |
| Trading | ||
| Volume | 1,099,722 shares | US#1,465/3,121 Sec#157/266 |
| Trading Value | $9M | US#2,501/3,121 Sec#211/266 |
| Per Share | ||
| EPS | $-2.06 | US—/3,121 Sec—/266 |
| BPS | $8.17 | US#1,988/3,121 Sec#87/266 |
Company Info
BioAge Labs, Inc., a clinical-stage biopharmaceutical company, develops therapeutic product candidates for metabolic diseases. The company’s technology platform and differentiated human datasets that allows users to identify targets based on insights into molecular changes that drive aging. Its lead product candidate includes BGE-102, an orally available brain-penetrant small-molecule NLRP3 inhibitor which is in Phase 1 clinical trail for the treatment of atherosclerotic cardiovascular disease, as well as for the treatment of diabetic macular edema and geographic atrophy; and develops APJ agonists for obesity, including programs targeting both oral and parenteral administration. The company has collaboration agreement with Novartis Pharma AG to identify and validate novel therapeutic drug targets by investigating the biological mechanisms that drive diseases related to aging and mediate. BioAge Labs, Inc. was incorporated in 2015 and is headquartered in Emeryville, California.